Aliases & Classifications for Cholera

MalaCards integrated aliases for Cholera:

Name: Cholera 12 76 53 59 55 43 3 44 15 73
Cholera Due to Vibrio Cholerae 12
Cholera - Vibrio Cholerae 12
Vibrio Cholerae Infection 53
Vibrio Cholerae 12

Characteristics:

Orphanet epidemiological data:

59
cholera
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),<1/1000000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1498
ICD9CM 35 001 001.0 001.9
MeSH 44 D002771
Orphanet 59 ORPHA173
MESH via Orphanet 45 D002771
UMLS via Orphanet 74 C0008354
ICD10 via Orphanet 34 A00.1 A00.9 A00.0
UMLS 73 C0008354

Summaries for Cholera

MedlinePlus : 43 Cholera is a bacterial infection that causes diarrhea. The cholera bacterium is usually found in water or food that has been contaminated by feces (poop). Cholera is rare in the US. You may get it if you travel to parts of the world with poor water and sewage treatment. Outbreaks can also happen after disasters. The disease is not likely to spread directly from person to person. Cholera infections are often mild. Some people don't have any symptoms. If you do get symptoms, they usually start 2 to 3 days after infection. The most common symptom is watery diarrhea. In some cases, the infection can be severe, causing lots of watery diarrhea, vomiting, and leg cramps. Because you quickly lose body fluids, you are at risk for dehydration and shock. Without treatment, you could die within hours. If you think that you might have cholera, you should get medical care right away. Doctors diagnose cholera with a stool sample or rectal swab. Treatment is the replacement of the fluid and salts that you lost through the diarrhea. This is usually with a rehydration solution that you drink. People with severe cases may need an I.V. to replace the fluids. Some of them may also need antibiotics. Most people who get fluid replacement right away will recover. There are vaccines to prevent cholera. One of them is available for adults in the U.S. Very few Americans need it, because most people do not visit areas that have an active cholera outbreak. There are also simple steps you can take to help to prevent cholera infection: Use only bottled or purified water for drinking, washing dishes, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Wash your hands often with soap and clean water Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables Centers for Disease Control and Prevention

MalaCards based summary : Cholera, also known as cholera due to vibrio cholerae, is related to pancreatic cholera and vipoma, and has symptoms including fever and pruritus. An important gene associated with Cholera is ARF1 (ADP Ribosylation Factor 1), and among its related pathways/superpathways are Metabolism of proteins and GPCR Pathway. The drugs Formaldehyde and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include skin, small intestine and eye.

Disease Ontology : 12 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.

NIH Rare Diseases : 53 Cholera is an infection of the small intestines that is caused by the bacterium Vibrio cholera. The condition can range from mild to severe and many affected people may have no obvious signs or symptoms. Approximately 5-10% of infected people will have severe disease with watery diarrhea and vomiting leading to rapid fluid loss, dehydration, and shock. If left untreated, this can cause acute renal failure, severe electrolyte imbalances, coma, or even death. People develop cholera when they eat food or drink water that is contaminated with Vibrio cholera. The condition occurs most often in places that lack water treatment and have poor sanitation and inadequate hygiene. Treatment aims to prevent dehydration and replace the fluids and salts that are lost through diarrhea.

Wikipedia : 76 Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae.... more...

Related Diseases for Cholera

Diseases related to Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 pancreatic cholera 12.1
2 vipoma 11.4
3 wdha syndrome 11.4
4 gastroenteritis 11.4
5 secretory diarrhea 11.3
6 diarrhea 10.3
7 pancreatitis 10.3
8 pertussis 10.2
9 mucositis 10.2
10 juvenile dermatitis herpetiformis 10.1 ADCY10 CD79A
11 shigellosis 10.1
12 aging 10.0
13 dysentery 10.0
14 acute diarrhea 10.0
15 cystic fibrosis 9.9
16 typhoid fever 9.9
17 cholecystitis 9.9
18 neuronitis 9.9
19 glioma 9.9
20 neuroblastoma 9.9
21 pasteurellosis 9.9
22 acalculous cholecystitis 9.9
23 plague 9.9
24 malaria 9.8
25 allergic conjunctivitis 9.8
26 pneumonia 9.8
27 conjunctivitis 9.8
28 influenza 9.8
29 fasciitis 9.8
30 necrotizing fasciitis 9.8
31 bronchitis 9.8 CD79A CFTR VIP
32 mite infestation 9.7 CD79A CFTR
33 pancreatic cancer 9.7
34 malignant glioma 9.7
35 lymphoma 9.7
36 chlamydia 9.7
37 erysipelas 9.7
38 diphtheria 9.7
39 cellulitis 9.7
40 retinitis 9.7
41 neuropathy 9.7
42 trichinosis 9.7
43 colorectal cancer 9.6
44 multiple endocrine neoplasia, type i 9.6
45 medulloblastoma 9.6
46 otitis media 9.6
47 prostate cancer 9.6
48 cerebellar hypoplasia 9.6
49 human immunodeficiency virus type 1 9.6
50 burns 9.6

Graphical network of the top 20 diseases related to Cholera:



Diseases related to Cholera

Symptoms & Phenotypes for Cholera

UMLS symptoms related to Cholera:


fever, pruritus

Drugs & Therapeutics for Cholera

Drugs for Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-00-0 712
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
9 Calcineurin Inhibitors Phase 4
10 Cholera Toxin Phase 4,Phase 3,Phase 1,Not Applicable
11 Cyclosporins Phase 4
12 Immunosuppressive Agents Phase 4
13 Methylprednisolone acetate Phase 4
14 Methylprednisolone Hemisuccinate Phase 4
15 Prednisolone acetate Phase 4
16 Prednisolone hemisuccinate Phase 4
17 Prednisolone phosphate Phase 4
18
Azithromycin Approved Phase 3 83905-01-5 55185 447043
19
Ciprofloxacin Approved, Investigational Phase 3,Phase 1 85721-33-1 2764
20
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6 23994
21
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 1
27 Micronutrients Phase 3,Phase 1,Phase 2
28 Trace Elements Phase 3,Phase 1,Phase 2
29 Erythromycin Estolate Phase 3
30 Erythromycin Ethylsuccinate Phase 3
31 Erythromycin stearate Phase 3
32 Acidophilus Nutraceutical Phase 3
33
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
34
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
35
Secnidazole Approved Phase 1, Phase 2 3366-95-8
36
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
37
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
38
Vitamin C Approved, Nutraceutical Phase 2,Phase 1 50-81-7 5785 54670067
39
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
40 Anthelmintics Phase 1, Phase 2
41 Antimitotic Agents Phase 1, Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Antiprotozoal Agents Phase 1, Phase 2
44 Astringents Phase 1, Phase 2
45 Dermatologic Agents Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Histamine Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Neurotransmitter Agents Phase 2
50 Guar Nutraceutical Phase 2

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Completed NCT01949675 Phase 4
2 Evaluation of a Boosting Regimen With Oral Cholera Vaccine Completed NCT01579448 Phase 4
3 Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Completed NCT01524640 Phase 4
4 A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children Completed NCT00760825 Phase 4
5 Mucosal Response in Immunocompromised Host Completed NCT01109914 Phase 4
6 Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Completed NCT00125008 Phase 4
7 New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Recruiting NCT03373669 Phase 4
9 VAXCHORA Pediatric Study Recruiting NCT03220737 Phase 4
10 Safety and Immunogenicity of a New Formulation of Euvichol® Unknown status NCT02502331 Phase 3
11 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea Unknown status NCT00534170 Phase 3
12 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Completed NCT02434822 Phase 3
13 Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Completed NCT02027207 Phase 3
14 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed NCT01895855 Phase 3
15 Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata Completed NCT00289224 Phase 3
16 Ciprofloxacin Multiple Dose for Adult Cholera Completed NCT00741052 Phase 3 Ciprofloxacin;Azithromycin
17 Zinc Supplementation in Cholera Patients Completed NCT00226616 Phase 3 Zinc
18 Single Dose Azithromycin in the Treatment of Adult Cholera Completed NCT00229944 Phase 3 Azithromycin
19 Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Completed NCT00142272 Phase 3 Ciprofloxacin
20 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed NCT02100631 Phase 3
21 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Completed NCT02094586 Phase 3
22 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
23 To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Completed NCT02164110 Phase 3
24 Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children Completed NCT02556996 Phase 3
25 Improving Rotavirus Vaccine Immune Response Completed NCT01825109 Phase 3
26 A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Completed NCT02133690 Phase 3
27 Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine Recruiting NCT03581734 Phase 3
28 Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Unknown status NCT00548054 Phase 2
29 Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Completed NCT02742558 Phase 2
30 Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata Completed NCT00119197 Phase 2
31 Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Completed NCT01233362 Phase 2
32 To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh Completed NCT01042951 Phase 2
33 Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Completed NCT02823899 Phase 1, Phase 2
34 Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Completed NCT00419133 Phase 2
35 Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Completed NCT00128011 Phase 2
36 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
37 Studies of Immune Responses to Orally Administered Vaccines in Developing Country Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
38 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Completed NCT02145377 Phase 2
39 Field Application of Shanchol in Adults in Bangladesh Completed NCT01762930 Phase 2 Shanchol
40 Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults Completed NCT00741637 Phase 2
41 Slow Versus Rapid Rehydration of Severely Malnourished Children Completed NCT02216708 Phase 2
42 Modified ORS Solution for Severely Malnourished Children Completed NCT01821586 Phase 2
43 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
44 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Active, not recruiting NCT03251495 Phase 2 Vaxchora
45 Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 Active, not recruiting NCT03576183 Phase 2
46 Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis Terminated NCT00751933 Phase 2
47 Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Terminated NCT00624975 Phase 2
48 Efficacy of iOWH032 in Dehydrating Cholera Withdrawn NCT02111304 Phase 2 iOWH032
49 Oral Rehydration Therapy in Burn Patients Unknown status NCT02124265 Phase 1 CeraLyte 90
50 Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules) Completed NCT03237663 Phase 1

Search NIH Clinical Center for Cholera

Cochrane evidence based reviews: cholera

Genetic Tests for Cholera

Anatomical Context for Cholera

MalaCards organs/tissues related to Cholera:

41
Skin, Small Intestine, Eye, T Cells, B Cells, Colon, Testes

Publications for Cholera

Articles related to Cholera:

(show top 50) (show all 1107)
# Title Authors Year
1
Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate. ( 29434590 )
2018
2
Dynamics of Cholera Epidemics with Impulsive Vaccination and Disinfection. ( 29425779 )
2018
3
Cholera outbreak caused by drinking contaminated water from a lakeshore water-collection site, Kasese District, south-western Uganda, June-July 2015. ( 29949592 )
2018
4
Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. ( 29317118 )
2018
5
Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. ( 29414267 )
2018
6
Uptake and intracellular fate of cholera toxin subunit b-modified mesoporous silica nanoparticle-supported lipid bilayers (aka protocells) in motoneurons. ( 29339186 )
2018
7
Fucosylated molecules competitively interfere with cholera toxin binding to host cells. ( 29411974 )
2018
8
Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. ( 29942084 )
2018
9
Empirical antibiotic treatment for children suffering from dysentery, cholera, pneumonia, sepsis or severe acute malnutrition. ( 29790843 )
2018
10
Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia. ( 29403111 )
2018
11
Surface Chemistry and Spectroscopic Study of a Cholera Toxin B Langmuir Monolayer. ( 29378405 )
2018
12
Cholera: an overview with reference to the Yemen epidemic. ( 29934743 )
2018
13
Use of cholera vaccines expands, raising hopes. ( 29439220 )
2018
14
A Systematic Review and Meta-Analysis of the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case-Control Studies. ( 29968551 )
2018
15
Oral cholera vaccine in cholera prevention and control, Malawi. ( 29904226 )
2018
16
Curbing cholera. ( 29899025 )
2018
17
Crisis-driven cholera resurgence switches focus to oral vaccine. ( 29962546 )
2018
18
The health economics of cholera: A systematic review. ( 29907482 )
2018
19
Probiotic strains detect and suppress cholera in mice. ( 29899022 )
2018
20
Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients. ( 29915319 )
2018
21
Systems, supplies, and staff: a mixed-methods study of health care workers' experiences and health facility preparedness during a large national cholera outbreak, Kenya 2015. ( 29890963 )
2018
22
A randomized, observer-blinded, equivalence trial comparing two variations of EuvicholAr, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines. ( 29895500 )
2018
23
No end to cholera without basic water, sanitation and hygiene. ( 29904216 )
2018
24
Long-run effects of early childhood exposure to cholera on final height: Evidence from industrializing Japan. ( 29349274 )
2018
25
Characterization of highly virulent multidrug resistant Vibrio cholerae isolated from a large cholera outbreak in Ghana. ( 29347965 )
2018
26
Places, attitudes and moments during the epidemics: representations of yellow fever and cholera in the city of Buenos Aires, 1867-1871. ( 29898124 )
2018
27
Cholera toxin enhances IL-17A production in both CD4<sup>+</sup>and CD8<sup>+</sup>cells via a cAMP/PKA-mediated IL-17A promoter activation. ( 29377102 )
2018
28
Comparative genomics of Vibrio cholerae O1 isolated from cholera patients in Bangladesh. ( 29981154 )
2018
29
Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti. ( 29942825 )
2018
30
Human evolutionary loss of epithelial Neu5Gc expression and species-specific susceptibility to cholera. ( 29912959 )
2018
31
Cyclical cholera outbreaks in Ghana: filth, not myth. ( 29903037 )
2018
32
Temporo-spatial dynamics and behavioural patterns of 2012 cholera epidemic in the African mega-city of Conakry, Guinea. ( 29448965 )
2018
33
A live vaccine rapidly protects against cholera in an infant rabbit model. ( 29899024 )
2018
34
AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera. ( 29903911 )
2018
35
Vibrio cholerae OmpU induces IL-8 expression in human intestinal epithelial cells. ( 29145158 )
2018
36
A case of otitis externa caused by non-01/non-0139 Vibrio cholerae after exposure at a Mediterranean bathing site. ( 29791126 )
2018
37
Spatial and population drivers of persistent cholera transmission in rural Bangladesh: Implications for vaccine and intervention targeting. ( 29413709 )
2018
38
GM1 ganglioside-independent intoxication by Cholera toxin. ( 29432456 )
2018
39
Highly affine and selective aptamers against cholera toxin as capture elements in magnetic bead-based sandwich ELAA. ( 29408200 )
2018
40
Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. ( 28916247 )
2017
41
Hetero-multivalent binding of cholera toxin subunit B with glycolipid mixtures. ( 28946063 )
2017
42
The DnaK Chaperone Uses Different Mechanisms To Promote and Inhibit Replication of<i>Vibrio cholerae</i>Chromosome 2. ( 28420739 )
2017
43
Eliminating Cholera Transmission in Haiti. ( 27959699 )
2017
44
Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera. ( 28319200 )
2017
45
Cost-of-illness of cholera to households and health facilities in rural Malawi. ( 28934285 )
2017
46
Putative protein VC0395_0300 from Vibrio cholerae is a diguanylate cyclase with a role in biofilm formation. ( 28647124 )
2017
47
The Role of Necroptosis, Apoptosis, and Inflammation in Fowl Cholera-Associated Liver Injury in a Chicken Model. ( 29337619 )
2017
48
Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. ( 27916412 )
2017
49
Global stability and uniform persistence of the reaction-convection-diffusion cholera epidemic model. ( 27879114 )
2017
50
Vibrio cholerae VciB Mediates Iron Reduction. ( 28348025 )
2017

Variations for Cholera

Expression for Cholera

Search GEO for disease gene expression data for Cholera.

Pathways for Cholera

Pathways related to Cholera according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 ARF1 ARF3 ARF4 ARF5 CFTR CGA
2
Show member pathways
13.59 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
3
Show member pathways
13.27 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
4
Show member pathways
13.03 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
5
Show member pathways
13.02 ARF1 ARF3 ARF4 ARF5 CGA NEU1
6
Show member pathways
13 ADCY1 CFTR CGA EGF GNAI1 GNAS
7 12.8 ADCY1 EGF GNAI1 GNAS PLCB1
8
Show member pathways
12.77 ADCY1 CD79A GNAI1 GNAS PLCB1
9
Show member pathways
12.66 ARF1 ARF3 ARF4 ARF5 ARL1
10
Show member pathways
12.63 ADCY1 CGA GNAI1 GNAS PLCB1
11
Show member pathways
12.63 ADCY1 EGF GNAI1 GNAS PLCB1
12
Show member pathways
12.63 ADCY1 ARF6 EGF GNAI1 GNAS PLCB1
13
Show member pathways
12.53 ADCY1 EGF GNAI1 GNAS
14
Show member pathways
12.52 ADCY1 GNAI1 GNAS PLCB1
15
Show member pathways
12.5 ADCY1 GNAI1 GNAS PLCB1
16
Show member pathways
12.44 ARF1 CFTR ERO1A GNAS
17 12.36 ARF1 ARF3 ARF5 ARF6
18
Show member pathways
12.34 ADCY1 GNAI1 GNAS PLCB1
19 12.33 ADCY1 GNAI1 GNAS PLCB1
20
Show member pathways
12.2 ADCY1 ADCY10 CFTR GNAI1 GNAS
21
Show member pathways
12.19 ADCY1 ARF1 ARF6 EGF GNAS PLCB1
22
Show member pathways
12.14 ADCY1 GNAI1 GNAS PLCB1
23
Show member pathways
12.14 ADCY1 CFTR GNAI1 GNAS
24
Show member pathways
12.05 ADCY1 CFTR GNAI1 GNAS PLCB1
25 12.01 ADCY1 ADCY10 GNAI1 PLCB1
26
Show member pathways
11.98 ADCY1 GNAS PLCB1
27 11.95 ADCY1 GNAI1 GNAS PLCB1
28 11.93 GNAI1 GNAS PLCB1
29 11.93 ADCY1 CGA GNAI1 GNAS VIP
30
Show member pathways
11.91 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
31 11.88 ADCY1 EGF GNAI1 PLCB1
32 11.86 ADCY1 GNAI1 GNAS PLCB1
33 11.85 GNAI1 GNAS PLCB1
34 11.85 ADCY1 GNAS PLCB1
35 11.81 ADCY1 CFTR GNAS PLCB1
36 11.8 ADCY1 GNAI1 GNAS
37 11.69 ADCY1 CFTR GNAS
38 11.64 GNAI1 GNAS PLCB1
39 11.6 GNAI1 GNAS PLCB1
40 11.59 CGA GNAI1 GNAS PLCB1
41 11.52 GNAI1 GNAS PLCB1
42 11.5 ADCY1 GNAI1 GNAS
43 11.5 ADCY1 EGF GNAI1 GNAS PLCB1
44 11.48 ADCY1 CGA GNAS
45 11.44 ADCY1 GNAS PLCB1
46 11.44 ADCY1 CGA GNAI1 GNAS
47 11.38 ARF1 ARF5 ARF6
48 11.35 ADCY1 GNAS PLCB1
49 11.09 ADCY10 GNAI1 GNAS PLCB1
50 10.87 ARF1 ARF6

GO Terms for Cholera

Cellular components related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.8 ADCY10 ARF1 ARF3 ARF5 GNAS
2 lysosomal membrane GO:0005765 9.62 CFTR EGF GNAI1 NEU1
3 intracellular GO:0005622 9.61 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
4 extracellular exosome GO:0070062 9.47 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
5 plasma membrane GO:0005886 10.15 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6
6 membrane GO:0016020 10.13 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6
7 cytoplasm GO:0005737 10 ADCY1 ADCY10 ARF1 ARF3 ARF4 ARF5

Biological processes related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein transport GO:0015031 9.83 ARF1 ARF3 ARF4 ARF5 ARF6
2 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 9.5 ARF3 ARF4 ARF5
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.43 ADCY1 GNAS VIP
4 cyclic nucleotide biosynthetic process GO:0009190 9.4 ADCY1 ADCY10
5 cAMP biosynthetic process GO:0006171 9.37 ADCY1 ADCY10
6 vesicle-mediated transport GO:0016192 9.35 ARF1 ARF3 ARF4 ARF5 ARF6
7 activation of phospholipase D activity GO:0031584 9.16 ARF4 ARL1
8 cellular response to forskolin GO:1904322 8.8 ADCY1 CFTR GNAI1

Molecular functions related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.56 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.37 GNAI1 GNAS
3 phosphorus-oxygen lyase activity GO:0016849 9.32 ADCY1 ADCY10
4 adenylate cyclase activity GO:0004016 9.26 ADCY1 ADCY10
5 GTPase activity GO:0003924 9.23 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
6 guanyl nucleotide binding GO:0019001 9.16 GNAI1 GNAS

Sources for Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....